Residency · Residency · Radiation Oncology

Anal Cancer: Definitive Chemoradiation (Nigro Protocol Evolution)

Overview

Squamous cell carcinoma of the anal canal is a relatively uncommon malignancy, but its incidence is increasing, particularly among HIV-positive individuals and men who have sex with men. The treatment landscape was transformed by the Nigro protocol, which combined concurrent chemotherapy with 5-fluorouracil (5-FU) and mitomycin C alongside radiation therapy. This approach demonstrated that chemoradiation therapy (CRT) could achieve both sphincter preservation and cure without the need for abdominoperineal resection (APR). Modern treatment techniques utilize intensity-modulated radiation therapy (IMRT) to reduce toxicity while maintaining excellent oncologic outcomes. Human papillomavirus (HPV) infection, primarily HPV-16, is the primary etiologic agent in over 90% of cases. For localized disease, the five-year overall survival ranges between 70% and 85%.

Historical Evolution

Pre-Nigro Era

Before the advent of chemoradiation, APR was the standard treatment for anal cancer. This was a mutilating surgery that resulted in a permanent colostomy. The five-year overall survival during this era varied from 40% to 70%, depending on the stage of the disease.

Nigro Protocol (1974)

The Nigro protocol was initially designed as a neoadjuvant chemoradiation regimen before planned APR. It consisted of 30 Gy external beam radiation therapy combined with concurrent 5-FU administered as a continuous infusion at 1000 mg/m² on days 1-4 and 29-32, along with mitomycin C at 15 mg/m² on day 1. Unexpectedly, early patients treated with this regimen demonstrated a pathologic complete response, with APR specimens frequently showing no residual tumor. This finding led to the adoption of CRT as a definitive curative treatment without surgery, marking a paradigm shift toward sphincter-preserving cure as the standard of care.

Landmark Clinical Trials

RTOG 98-11 (Ajani et al., 2008; 5-year update 2012)

This phase III trial compared mitomycin C/5-FU plus radiation therapy to an induction regimen of cisplatin/5-FU followed by cisplatin/5-FU with radiation. The five-year overall survival was 78.3% in the mitomycin C arm versus 70.7% in the cisplatin arm, a difference that was not statistically significant. However, disease-free survival at five years was significantly better with mitomycin C (67.8% vs. 57.8%, p=0.006), and the colostomy rate was lower (10% vs. 19%, p=0.02). The conclusion was that mitomycin C/5-FU remains the standard regimen, as cisplatin did not improve outcomes and was inferior in terms of disease-free survival and colostomy-free survival.

ACT II (James et al., 2013)

This phase III trial employed a 2x2 factorial design to compare cisplatin versus mitomycin C in combination with 5-FU and radiation, with or without maintenance chemotherapy using cisplatin/5-FU. Cisplatin-based CRT was found to be non-inferior to mitomycin C-based CRT for complete response at 26 weeks. Maintenance chemotherapy provided no benefit. These results confirmed mitomycin C/5-FU plus radiation as the standard, given that cisplatin was not superior and is associated with greater toxicity.

ACCORD-03

This phase III trial evaluated the role of induction chemotherapy and radiation dose escalation. Induction chemotherapy with cisplatin/5-FU prior to CRT showed no benefit. Increasing the radiation boost dose from 15 Gy to 20-25 Gy did not significantly improve colostomy-free survival. The standard dose of 45 Gy plus a 15-20 Gy boost remains adequate for most patients.

ACT-5 / PersonaLAR / EA2176

Ongoing trials are investigating treatment de-escalation for low-risk patients (T1-2 N0) and intensification for high-risk patients (T3-4 or node-positive). These studies also explore the integration of immunotherapy agents such as nivolumab and pembrolizumab with CRT.

Radiation Therapy Technique

Dose and Fractionation

The radiation therapy regimen typically involves a phase 1 elective dose of 36-42 Gy delivered in 20-23 fractions to elective nodal regions. Gross disease, including involved nodes, receives 50.4-54 Gy. The primary tumor boost dose depends on stage: T1-T2 N0 tumors receive a total of 50.4-54 Gy, whereas T3-T4 or node-positive tumors receive 54-59.4 Gy. The simultaneous integrated boost (SIB) technique allows different dose levels to be delivered within a single treatment plan. Treatment breaks should be minimized, as prolonged interruptions are associated with worse outcomes.

Target Volume Delineation

Primary Tumor CTV

The gross tumor volume (GTV) for the primary tumor is defined based on clinical examination and imaging modalities such as CT, MRI, and PET-CT. The clinical target volume (CTV) for the primary tumor includes the GTV plus a 2-2.5 cm margin, encompassing the entire anal canal, perianal tissue, and mesorectal space.

Nodal CTV

Bilateral inguinal nodal coverage is standard for all anal canal tumors, including clinically node-negative T1N0 tumors, due to the high risk of inguinal nodal recurrence without coverage. Exceptions may be made for very small perianal margin tumors, although this remains controversial. Internal iliac nodes are included bilaterally. External iliac nodes are included if inguinal nodes are involved or for T4 tumors invading anterior structures. Presacral and mesorectal nodes are also included within the CTV.

Contouring Guidelines

Contouring follows the Radiation Therapy Oncology Group (RTOG) consensus atlas for anorectal CTV delineation (Myerson et al.). The inguinal CTV is contoured along the femoral vessels from the inguinal ligament to the saphenofemoral junction. The internal iliac CTV follows the internal iliac vessels from the common iliac bifurcation to the obturator fossa.

IMRT/VMAT

IMRT or volumetric modulated arc therapy (VMAT) is strongly recommended as it reduces acute skin, gastrointestinal, and genitourinary toxicity compared to three-dimensional conformal radiation therapy (3D-CRT). The RTOG 0529 phase II dose-painting IMRT study demonstrated lower rates of grade 2 or higher hematologic, gastrointestinal, and dermatologic toxicity compared to RTOG 98-11, which used 3D-CRT. Bone marrow sparing is an important consideration; minimizing radiation dose to pelvic bone marrow regions such as the iliac crests and lumbosacral spine reduces hematologic toxicity during CRT. Daily image-guided radiation therapy (IGRT) is recommended for accurate setup verification.

OAR Constraints

Organ-at-risk (OAR) constraints include limiting the small bowel volume receiving 45 Gy to less than 20 cc and the volume receiving 35 Gy to less than 150 cc. For femoral heads, the volume receiving 40 Gy should be under 35%, and the volume receiving 44 Gy under 5%. The bladder should receive less than 10% volume at 50 Gy and less than 35% at 40 Gy. Iliac bone marrow sparing targets include V10 <90%, V20 <80%, V30 <60%, and V40 <40%. Radiation to external genitalia should be minimized, and patients should be counseled about potential skin desquamation and effects on sexual function. Moist desquamation of the perineal skin is common and expected; adherence to skin care protocols is essential.

Concurrent Chemotherapy

Standard Regimen

The standard concurrent chemotherapy regimen includes 5-FU at 1000 mg/m² per day as a continuous infusion on days 1-4 and 29-32, combined with mitomycin C administered as a 10-12 mg/m² intravenous bolus on day 1 only, although some protocols administer a second dose on day 29. An alternative regimen uses oral capecitabine at 825 mg/m² twice daily on radiation days, replacing the 5-FU infusion for convenience; growing evidence supports the equivalence of capecitabine to 5-FU in this setting.

Toxicity

Myelosuppression is a significant toxicity, with mitomycin C causing cumulative thrombocytopenia and neutropenia; therefore, weekly complete blood count monitoring is essential. Hemolytic uremic syndrome is a rare but serious complication associated with mitomycin C. Perianal dermatitis is universal, with grade 3 moist desquamation occurring in 40-60% of patients. Treatment breaks should be minimized, and therapy should continue through grade 2 toxicity when it is safe to do so.

Response Assessment and Salvage

Assessment Timeline

Clinical examination, including digital rectal exam, is performed at 8-12 weeks after completion of CRT. Tumors often continue to regress for up to six months post-treatment, so premature biopsy or salvage surgery should be avoided. PET-CT imaging at 3-6 months post-CRT helps differentiate residual scarring from persistent disease. Biopsy is reserved for cases with progressive disease or a persistent mass beyond six months.

Salvage APR

Salvage APR is indicated for persistent or recurrent disease after CRT. Five-year salvage overall survival ranges from 30% to 60%, depending on disease extent. The primary functional endpoint of definitive CRT is colostomy-free survival, and approximately 10-30% of patients ultimately require APR.

<image>An illustration of the IMRT target volume delineation for anal canal cancer on an axial CT image at the level of the ischial tuberosities. The GTV-primary (red) is shown in the posterior anal canal. The CTV (blue) encompasses the anal canal, mesorectum, bilateral inguinal regions, and internal iliac nodal stations. The dose color-wash shows the SIB technique with three dose levels: 54 Gy to the primary (hot center), 50.4 Gy to involved nodes, and 42 Gy to elective nodal regions. Key OARs (bladder, small bowel, femoral heads, external genitalia) are contoured.</image>

<image>A historical timeline showing the evolution of anal cancer treatment from APR (pre-1974) through the Nigro protocol (1974), UKCCCR ACT I (1996), RTOG 98-11 (2008), ACT II (2013), and RTOG 0529 IMRT (2014). At each milestone, the standard regimen, key finding, and impact on practice are annotated. The transition from surgery-first to sphincter-preserving CRT to IMRT-based CRT with reduced toxicity is highlighted.</image>

<image>A dose-volume histogram comparison from RTOG 0529 showing the dosimetric advantage of IMRT over 3D-CRT for anal cancer. Curves for the small bowel, bladder, femoral heads, and pelvic bone marrow demonstrate lower doses to OARs with IMRT. Adjacent bar graphs compare grade 2+ GI, GU, and hematologic toxicity rates between RTOG 98-11 (3D-CRT) and RTOG 0529 (IMRT), showing significant reductions with IMRT.</image>

Key Clinical Pearls

Mitomycin C combined with 5-FU and concurrent radiation remains the standard regimen for anal cancer, as the RTOG 98-11 trial definitively showed that cisplatin does not improve outcomes and is associated with worse disease-free survival and higher colostomy rates. IMRT is mandatory for anal cancer treatment because RTOG 0529 demonstrated significant reductions in acute toxicity compared to 3D-CRT, making older techniques obsolete. Bilateral inguinal nodal irradiation is standard for all anal canal tumors, even if clinically node-negative, due to the unacceptably high inguinal nodal recurrence rate without coverage. Clinicians should avoid rushing to biopsy or APR for residual disease after CRT, since tumor regression may continue for up to six months, and premature intervention can lead to unnecessary colostomies. Bone marrow-sparing IMRT is a critical technique to reduce hematologic toxicity during CRT, which is especially important given the myelosuppressive effects of mitomycin C.

References

• Nigro ND et al. "Combined therapy for cancer of the anal canal: a preliminary report." Dis Colon Rectum. 1974;17(3):354-356.
• Ajani JA et al. "Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial." JAMA. 2008;299(16):1914-1921.
• James RD et al. "Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial." Lancet Oncol. 2013;14(6):516-524.
• Kachnic LA et al. "RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal." Int J Radiat Oncol Biol Phys. 2013;86(1):27-33.
• Myerson RJ et al. "Elective clinical target volumes for conformal therapy in anorectal cancer: a Radiation Therapy Oncology Group consensus panel contouring atlas." Int J Radiat Oncol Biol Phys. 2009;74(3):824-830.

Read this lecture as Markdown